Omeros Stock Discussion

$Omeros (OMER.US)$ Sky rocket

$Omeros (OMER.US)$ naughty naughty . go back to your room .

$Omeros (OMER.US)$ Weak hand lose their shares.

$Omeros (OMER.US)$ Going to rise.

$Omeros (OMER.US)$ 1.85MM short volume.. crash coming

$Omeros (OMER.US)$ Rise fast drop fast

$Omeros (OMER.US)$ the chart from yesterday looks very much like a typical AMC chart

$Omeros (OMER.US)$
What the hell???!!!

$Omeros (OMER.US)$
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Omeros announced that its MASP-3 inhibitor zaltenibart (OMS906) received rare pediatric disease designation from the FDA for treating C3 glomerulopathy (C3G), an ultra-rare renal disorder affecting children and young adults. The company plans to initiate Phase 3 trials for C3G in 2024. Zaltenibart is also being developed for paroxysmal nocturnal hemoglob...

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$  Phase 2
$Supernus Pharmaceuticals (SUPN.US)$  Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$  Phase 2a
$MorphoSys (MOR.US)$  Phase 2
$Nuvation Bio (NUVB.US)$  Phase 2
$ALX Oncology (ALXO.US)$  Phase 2
$BioXcel Therapeutics (BTAI.US)$  Phase 2
$Purple Biotech (PPBT.US)$  Phase 2
$Arcus Biosciences (RCUS.US)$  Phase 2
$Medicenna Therapeutics (MDNAF.US)$  Phase 2b
$Affimed NV (AFMD.US)$  Phase 2
$Barinthus Biotherapeutics (BRNS.US)$  Phase 2b...